Halsey Drug
Executive Summary
Generic firm's Brooklyn plant resumes shipment of its combination acetaminophen, butalbital and caffeine 325 mg/50 mg/40 mg tablet the week of Aug. 23 and expects to resume shipment of two to three additional solid dosage products "shortly," firm reports in an Aug. 26 financial release. Shipment of oxycodone/acetaminophen 5 mg/325 mg and 5 mg/500 mg capsules from its Brooklyn facility resumed in early August. Halsey had suspended shipment of all non-liquid products from the Brooklyn plant under a June 29 consent decree with FDA ("The Pink Sheet" July 5, T&G-11).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth